Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Iclusig

Iclusig 5 mg hard capsules · Abschnitt 4.8 · PDF-Seite 63–64

HOS-128578 · Präparat HOS-096579

63  Ponatinib in combination with reduced- System organ class Frequency intensity chemotherapy Adverse reactions Tachycardia Palpitations Pericardial effusion Common Atrial fibrillation Cardiac disorders Sinus bradycardia Angina pectoris Cardiac failure Uncommon Acute myocardial infarction Cardiac failure congestive Very common Hypertension Deep vein thrombosis Common Superficial vein thrombosis Vascular disorders Embolism Peripheral arterial occlusive disease Uncommon Peripheral coldness Thrombosis Very common Cough Dyspnoea Respiratory, thoracic and Oropharyngeal pain mediastinal disorders Common Pleural effusion Dysphonia Pulmonary embolism Constipation Nausea Vomiting Very common Stomatitis Diarrhoea Abdominal pain Abdominal pain upper Gastrointestinal disorders Dyspepsia Abdominal distension Abdominal discomfort Common Pancreatitis Gastritis Pancreatitis acute Uncommon Mouth haemorrhage Hepatotoxicity Hyperbilirubinaemia Common Hypertransaminasaemia Hepatobiliary disorders Hepatitis toxic Drug-induced liver injury Uncommon Hepatobilliary disease Liver injury Rash Very common Dry skin Skin and subcutaneous tissue Pruritus disorders Common Alopecia Rash maculo-papular Back pain Musculoskeletal and Pain in extremity Very common connective tissue disorders Arthralgia Myalgia

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.